Advertisement

Proteostasis Therapeutics Inc. of Cambridge has added to its three-year-old Series A funding, boosting it from a planned $5 million to taking $70.6 million of what is now a planned $81.8 million round.

In the 2008 financing round, the lead investor was HealthCare Ventures of Cambridge, with participation by Fidelity Biosciences, as well as Genzyme Ventures and Novartis Option Fund, the venture investment units of Genzyme Corp. and Novartis AG, respectively. A new document filed with the U.S. Securities and Exchange Commission lists executives at all of those firms as related persons in the amended round.

SOURCE

Advertisement
Advertisement